Key result
Moxonidine improved global cardiac performance, reduced collagen deposition, regressed left ventricular hypertrophy, and attenuated cytokines in spontaneously hypertensive rats.
Why the study?
Does moxonidine improve cardiac structure and performance in spontaneously hypertensive rats?
Does moxonidine improve cardiac structure and performance in spontaneously hypertensive rats?
Moxonidine improves cardiac structure and performance in spontaneously hypertensive rats through inhibition of cytokines, p38 MAPK, and Akt, suggesting potential benefits of cardiac-selective I1-receptor agonists.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for I1-receptor agonism in hypertensive remodeling; leaves open translation to human trials.
Aceros et al. (2011) studied Hypertension (spontaneously hypertensive rats). Moxonidine vs. 0 µg·kg(-1)·h(-1) was evaluated on Cardiac function, structure, and inflammatory markers. Moxonidine improved global cardiac performance, reduced collagen deposition, regressed left ventricular hypertrophy, and attenuated cytokines in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: